Paris, France – 19 February, 2015 – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced that Professor Robert Langer, Institute Professor at the Massachusetts Institute of Technology (MIT), has become Scientific Advisor to Nanobiotix.
Laurent Levy, CEO of Nanobiotix, commented: "We really appreciate that Professor Langer joined us as a Scientific Advisor. Professor Langer is a globally acknowledged nanomedicine expert and serial business innovator, and his involvement will be an asset for our technologies, our development and expansion beyond cancer."
Professor Langer presides over the largest academic biomedical engineering laboratory in the world. His laboratory is centered in the David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology. His team has more than 100 researchers including chemists, biologists, materials science engineers and computer scientists.
He is also a Principle Investigator at the MIT-Harvard Center for Cancer Nanotechnology Excellence, one of eight Centers of Cancer Nanotechnology Excellence awarded by The National Cancer Institute (NCI), part of the National Institutes of Health (NIH).
Beyond his extensive involvement and leadership in MIT's scientific community, Professor Langer's research has spawned a vast array of innovative and disruptive technologies. He holds over 1 000 patents in diverse areas of biomedical technology and has been involved in the launch or acceleration of numerous biotech companies including BIND Therapeutics, Enzytech and Pervasis as examples.
Professor Langer said: "Radical and disruptive technologies are always required. An interdisciplinary approach to research and development is critical to ensure that these technologies are developed to their fullest potential. I see NanoXray technology as one of the technologies that could make a significant difference to disease treatment. Nanobiotix has very exciting and innovative projects and I look forward to working with the Team."
In September 2014, Nanobiotix opened its US affiliate in the Boston Life Science hub, in Cambridge MA. The location provides access to a critical mass of academic and medical institutions as well as biopharmaceutical industries, and will ensure access to the research community and clinical expertise in the US.
- ENDS -
Notes to Editors
About NANOBIOTIX: www.nanobiotix.com
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The company's first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of cancers including Soft Tissue Sarcoma, Head and Neck Cancer, Liver Cancers, Prostate Cancer, Breast Cancer, Glioblastoma, etc., via multiple routes of administration.
Nanobiotix's lead product NBTXR3, based on NanoXray, is currently under clinical development for Soft Tissue Sarcoma and locally advanced Head and Neck Cancer. The company has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.
Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP). The company, based in Paris, France, opened an affiliate office in the Boston area of the US in September, 2014.
Issued for and on behalf of Nanobiotix by Instinctif Partners.
For more information please contact:
Head of Communication and Public Affairs
France - NewCap
Outside France - Instinctif Partners
Melanie Toyne Sewell / Ruth Ashton / Emma Barlow
+33 (0)1 40 26 07 55